Blackstone Life Sciences Announces $455 Million Collaboration With Boston Scientific To Develop VITALYST Heart Pump

Blackstone Life Sciences has announced a $455 million collaboration with Boston Scientific Corporation to co-fund the development of the VITALYST Temporary Percutaneous Transvalvular Circulatory Support System, a next-generation miniature heart pump designed to support patients experiencing cardiogenic shock following a heart attack.

The agreement represents the first collaboration between Blackstone Life Sciences and Boston Scientific to jointly fund the development of a Boston Scientific medical technology.

The VITALYST system is being developed to increase cardiac output and improve blood circulation to the brain and other vital organs in patients experiencing acute myocardial infarction cardiogenic shock (AMI-CS).

Cardiogenic shock is a life-threatening medical emergency that occurs when the heart cannot pump sufficient blood to meet the body’s needs. The condition can develop following a severe heart attack or other cardiac complications and is associated with a high risk of mortality despite advances in cardiovascular treatment.

Boston Scientific is developing VITALYST to address several challenges associated with existing mechanical circulatory support technologies, including treatment effectiveness, patient safety, and ease of use for physicians managing critically ill patients.

The miniature pump is intended to provide temporary mechanical support to the heart, helping maintain blood flow while medical teams treat the underlying cardiac emergency.

The collaboration combines Boston Scientific’s experience in cardiovascular device development and commercialization with Blackstone Life Sciences’ investment capabilities and expertise in advancing medical technologies through clinical development.

The funding arrangement will support continued development of the VITALYST program as Boston Scientific works toward delivering a new treatment option for patients experiencing severe cardiac complications.

The investment also reflects the growing role of alternative financing partnerships in the medical technology industry, where developing complex devices can require substantial capital commitments before commercial availability.

For Blackstone Life Sciences, the agreement represents an opportunity to support a potentially important cardiovascular technology through a partnership with an established medical device manufacturer.

Blackstone Life Sciences manages approximately $18 billion in assets and invests across the life sciences sector, including pharmaceutical development, biotechnology, and medical technology.

Its investment approach combines financial resources with operational expertise to help companies develop and commercialize treatments and technologies intended to address significant unmet medical needs.

The VITALYST collaboration expands Blackstone Life Sciences’ involvement in medical device development while supporting Boston Scientific’s efforts to advance mechanical circulatory support technologies for patients facing life-threatening cardiovascular emergencies.

KEY QUOTES:

“Boston Scientific has built a leading cardiovascular franchise, with deep expertise in developing and commercializing transformative technologies for patients and physicians. We believe the VITALYST system has the potential to improve on the efficacy and safety of currently available mechanical circulatory support technologies, and this collaboration reflects our ability to help leaders in innovation bring important new medical devices to patients.”

Nicholas Galakatos, Ph.D., Global Head Of Blackstone Life Sciences